Biogen sets $55K annual price tag on new MS drug
Two days after the U.S. approval of a new multiple sclerosis drug at least one analyst expects to eventually hit $6 billion in annual sales, Biogen Idec announced a $54,900 annual price per patient for Tecfidera.
Join the discussion below, or Read more at Business Journal.
#1 Apr 1, 2013
Robbery. 14 year patent protection should have kept this drug around 20k a year. All MS drugs are overpriced for their efficacy. How much will the upcoming drugs that may reverse the damage cost? 150k 200k a year? Where is the limit? I believe Pharma should be paid, but this is robbery. Just how much did it cost them not to have MS, Lupus, RA, etc? So glad the government is trying to protect me from guns and gay marriage instead of things I can't provide my own protection against.
Add your comments below
|Transgender teenager Jazz Jennings signed to be... (Mar '15)||Aug 8||TipsyFromCentralC...||4|
|PharMerica expects growth after KKR buys it for...||Aug 7||Common_sense||1|
|Appalachian congressmen ask FDA to reclassify O... (May '07)||Aug 1||Viking Power||38|
|Gov't report: Efforts to reduce US uninsured st...||Jul '17||Repeal obama care||23|
|Walgreens and LabCorp Collaborate to Bring Pati...||Jun '17||wagnous||1|
|CDC panel again advises against FluMist||Jun '17||VACCINES MAIM KILL||1|
|Ring-ring: Cellphone interrupts Supreme Court h...||Apr '17||better call Saul||1|
Find what you want!
Search Biotech Forum Now
Copyright © 2017 Topix LLC